Innoviva Total Depreciation and Amortization - Cash Flow 2010-2025 | INVA
Innoviva total depreciation and amortization - cash flow from 2010 to 2025. Total depreciation and amortization - cash flow can be defined as the total amount of depreciation and amortization listed on the Cash Flows Statement
Innoviva Annual Total Depreciation and Amortization - Cash Flow
(Millions of US $) |
| 2024 |
$42 |
| 2023 |
$38 |
| 2022 |
$22 |
| 2021 |
$23 |
| 2020 |
$22 |
| 2019 |
$19 |
| 2018 |
$21 |
| 2017 |
$19 |
| 2016 |
$17 |
| 2015 |
$17 |
| 2014 |
$16 |
| 2013 |
$8 |
| 2012 |
$7 |
| 2011 |
$8 |
| 2010 |
$6 |
| 2009 |
$6 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.166B |
$0.359B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
